Access to BAY2927088 for Treating Advanced Non-Small Cell Lung Cancer with HER2 Mutation

Sponsor: Bayer

Expanded Access
Sponsor score: 60

ClinicalTrials ID:NCT06761976

Provider View

This program provides access to the drug BAY2927088 for patients with advanced non-small cell lung cancer (NSCLC) who have a specific HER2 gene mutation and no other treatment options.

Patient Parameters

Program Overview

The goal of this program is to offer the drug BAY2927088 to patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has a mutation in the HER2 gene. This is for patients who have no other available treatment options.

Eligibility Criteria

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.